Restart Life Sciences Corp.
NMLSF
$0.032
-$0.0265-45.30%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -20.80K | 300.00 | 300.00 | 300.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -20.80K | 300.00 | 300.00 | 300.00 |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -20.80K | 300.00 | 300.00 | 300.00 |
| SG&A Expenses | 452.70K | 390.10K | 462.30K | 591.90K | 838.00K |
| Depreciation & Amortization | 1.60K | 1.70K | 1.80K | 1.90K | 2.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 454.80K | 392.80K | 465.20K | 623.50K | 893.20K |
| Operating Income | -454.80K | -413.60K | -464.80K | -623.10K | -892.80K |
| Income Before Tax | 163.70K | 9.60K | -464.50K | -623.70K | -907.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.16 | 0.01 | -0.46 | -0.62 | -0.91 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 163.70K | 9.60K | -464.50K | -623.70K | -907.00K |
| EBIT | -454.80K | -413.60K | -464.80K | -623.10K | -892.80K |
| EBITDA | -453.10K | -411.70K | -462.90K | -621.00K | -890.50K |
| EPS Basic | 0.01 | 0.00 | -0.03 | -0.04 | -0.06 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.03 | -0.04 |
| EPS Diluted | 0.00 | -0.01 | -0.04 | -0.05 | -0.07 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.03 | -0.04 |
| Average Basic Shares Outstanding | 61.12M | 59.16M | 59.05M | 58.95M | 58.70M |
| Average Diluted Shares Outstanding | 63.44M | 59.65M | 59.05M | 58.95M | 58.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |